VIP + TB-500 Research Data

Natural Aminos Research Formula of the Day — VIP & TB-500

Benefits

VIP (Vasoactive Intestinal Peptide) is a naturally occurring 28-amino-acid neuropeptide with wide-ranging immunomodulatory, anti-inflammatory, and vasodilatory activity. Research links it to suppressing pro-inflammatory cytokine release, enhancing regulatory T-cells, relaxing smooth muscle in blood vessels and airways, and stimulating bone repair and angiogenesis. Notably, VIP is one of the few anti-inflammatory neuropeptides found to be abnormally absent in patients with chronic inflammatory response syndrome (CIRS).

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4 (TB4), a naturally occurring 43-amino-acid protein and the most abundant beta-thymosin in the human body. As a primary regulator of actin, it sequesters monomeric G-actin and influences cell motility and cytoskeletal dynamics. Research links it to promoting cell migration, angiogenesis, and tissue repair in muscle, tendon, ligament, bone, and skin, along with downregulation of NF-κB, a major driver of chronic inflammation.

Uses

VIP has been studied across pulmonary hypertension and COPD (inhaled formulations), acute respiratory distress syndrome and severe COVID-19 (IV formulations), and — most relevant to how it's marketed today — chronic inflammatory response syndrome (CIRS) following exposure to water-damaged/moldy buildings, used off-label as a nasal spray. TB-500 is most discussed in sports medicine and injury-recovery contexts — chronic tendinopathies, muscle strains, ligament injuries — with thymosin beta-4 research also extending into ophthalmic formulations for dry eye, hair growth, and cardiac remodeling after injury.

Published Research

VIP has a surprisingly deep and varied human trial record for a peptide marketed largely in wellness/functional medicine spaces. A double-blind, placebo-controlled trial in 34 severe COPD patients tested VIP inhalation over 3 months. In severe COVID-19, an initial clinical trial using intravenous VIP found greater survival likelihood from respiratory failure at day 60 in critically ill patients, and Aviptadil, a synthetic VIP formulation, was tested in ACTIV-3b/TESICO-affiliated trials. For CIRS specifically, a study surveying 15 patients with refractory symptoms who received off-label exogenous VIP nasal spray found mean symptom scores decreased from 12.9 to 3.3 (a 74% reduction), alongside changes in over 700 genes related to metabolism and immune function — though this CIRS-specific research comes from a narrow, single clinical framework rather than a broad multi-center trial. As of May 2026, VIP sits on the FDA's Category 1 list of bulk substances under active regulatory evaluation for compounding, meaning it hasn't received premarket safety/effectiveness review.

TB-500's evidence base is described in a 2026 scoping review as deep and mechanistically coherent, but overwhelmingly preclinical — centered on cell and animal studies of actin biology, cell migration, and repair. Where TB4 research has reached actual clinical study, it's narrow: ophthalmic formulations have gone from bench to bedside for eye conditions. Animal studies found it induced hair growth in mice and reduced cardiac scarring after induced myocardial infarction, and a 2024 pharmacokinetic study quantified TB-500 and its metabolites in rats and in vitro. The FDA lists the TB4 fragment among bulk drug substances flagged for significant safety risk in compounding, citing limited human exposure and safety data, and WADA classifies TB4 and its derivatives, including TB-500, as prohibited substances.

No published research has evaluated VIP and TB-500 in combination. Each rests on an entirely separate evidence base and mechanism — systemic immune/anti-inflammatory and vasoactive signaling for VIP, localized actin/cytoskeletal tissue-repair biology for TB-500.

Why More Research Is Needed

VIP's gap depends heavily on the application: its COPD, COVID/ARDS, and pulmonary hypertension research includes genuine randomized, placebo-controlled trials, while its most heavily marketed current use — CIRS/mold illness treatment — rests on a single, narrow study from one clinical framework. Its Category 1 FDA compounding status also reflects real, active regulatory uncertainty. TB-500's central gap is the mismatch between a substantial preclinical literature and thin human data — most claims about systemic tissue repair in people haven't been tested in controlled human trials, and regulators have specifically flagged limited human safety data as a concern. Neither compound has been studied in combination with the other, so any stacking rationale here remains unverified.

Sources

ClinicalTrials.gov — Vasoactive Intestinal Peptide in COPD (NCT00464932)

PMC — Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy: Shedding of ACE2 and TMPRSS2 via ADAM10

ClinicalTrials.gov — Aviptadil for Severely Ill Inpatients With COVID-19 (ACTIV-3b/TESICO)

ResearchGate — Vasoactive Intestinal Polypeptide (VIP) Corrects Chronic Inflammatory Response Syndrome (CIRS) Acquired Following Exposure to Water-Damaged Buildings

MoldCo — VIP Nasal Spray for CIRS: Evidence and Questions

MDPI Applied Sciences — Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review (2026)

American Peptides — TB-500 / Thymosin Beta-4 Studies: What the Research Shows

PMC — Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals

Hashtags

#Peptidetherapy #PeptideResearch #PeptideScience #Biohacking #ResearchPeptides #ScienceBased #TB500 #WellnessScience #TissueRepair #MuscleRecovery #InjuryRecovery #RecoveryScience #CellularHealth